Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 10/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | PDE2A | O00408 | 1/20 | 0.54 |
| ▸ | TYMP | P19971 | 1/20 | 0.53 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21192264 | 1.00 | SLC29A1 (0.62) | SLC29A1STAT6ADORA3HSPA5TP53 | |
| SCHEMBL1140717 | 0.86 | SLC29A1 (0.64) | SLC29A1STAT6ADORA3HSPA5TP53 | |
| SCHEMBL622588 | 0.85 | ADORA1 (0.69) | SLC29A1STAT6ADORA3HSPA5SMN1; SMN2 | |
| SCHEMBL8902195 | 0.85 | ADORA3 (0.62) | SLC29A1ADORA3TP53SMN1; SMN2ADORA1 | |
| SCHEMBL19488389 | 0.84 | RXFP1 (0.51) | SLC29A1STAT6ADORA3HSPA5TP53 | |
| SCHEMBL21191887 | 0.84 | RXFP1 (0.51) | SLC29A1STAT6ADORA3HSPA5TP53 | |
| SCHEMBL19488387 | 0.83 | TP53 (0.57) | SLC29A1ADORA3TP53SMN1; SMN2 | |
| SCHEMBL240981 | 0.81 | SMN1; SMN2 (0.77) | SLC29A1STAT6ADORA3TP53SMN1; SMN2 | |
| SCHEMBL672036 | 0.81 | SMN1; SMN2 (0.77) | SLC29A1STAT6ADORA3TP53SMN1; SMN2 | |
| SCHEMBL7134319 | 0.81 | SMN1; SMN2 (0.77) | SLC29A1STAT6ADORA3TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225643-A1 | NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT | CORNELL UNIVERSITY (US) | 2019-07-25 | — | — | US | disclosed |
| WO-2017180981-A1 | NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT | CORNELL UNIVERSITY (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225643-A1 | NOVEL NUCLEOSIDE ANALOGS AND USE THEREOF IN THERAPEUTIC TREATMENT | DCK, NME4, ENTPD5 | SLC29A1 80/4885STAT6 915/4885ADORA3 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.